Herrador Galindo, LorenaGayán Ordás, JaraLlatjós, RogerClaver i Garrido, EduardGonzález Costello, José2025-07-082025-07-082025-03-312514-2119https://hdl.handle.net/2445/222080Background Endomyocardial fibrosis (EMF) is a challenging disease that leads to severe heart failure (HF) due to progressive fibrosis. Diet, parasitic infections, autoimmune disorders, and genetic predisposition have been advocated in EMF pathogenesis, and treatment options for EMF are limited with scarce evidence supporting heart transplantation (HTx).Case summary A 38-year-old man was diagnosed with EMF with biventricular involvement. The diagnostic work-up ruled out eosinophilia, infections, and autoimmune conditions. The patient rapidly deteriorated, leading to cardiogenic shock with multiorgan failure, and an emergency HTx was performed. Three months later, the graft developed biventricular hypertrophy with atrial fibrosis and the endomyocardial biopsy (EMB) showed extensive inflammation and myocardial damage, compatible with Grade 2R (G3a) cellular rejection. After steroid pulses, the follow-up EMB reveals subendocardial fibrosis and microcalcifications, suggesting the possibility of an EMF recurrence. Nevertheless, the patient had a good clinical outcome, remaining asymptomatic with good graft function 2 years after the transplant.Discussion This is the first reported case of suspected EMF recurrence following HTx. Given the unknown pathogenesis of EMF, close monitoring is crucial, though HTx appears to be a viable and successful treatment option for these patients.5 p.application/pdfengcc-by-nc (c) Herrador Galindo et al., 2025http://creativecommons.org/licenses/by-nc/3.0/es/Trasplantament cardíacMiocarditisHeart transplantationMyocarditisinfo:eu-repo/semantics/article2025-06-19info:eu-repo/semantics/openAccess40322492